Regular papers

• Select this article
  • Adena E Rosenblatt,
  • Maria Ines Garcia,
  • Leah Lyons,
  • Yingqiu Xie,
  • Carol Maiorino,
  • Laurent Désiré,
  • Joyce Slingerland,
  • and Kerry L Burnstein

  Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer

  Endocr Relat Cancer 18 (2) 207-219, doi:10.1677/ERC-10-0049 first published on 30 November 2010
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
• Select this article
  • Alicia A Tone,
  • Carl Virtanen,
  • Patricia A Shaw,
  • and Theodore J Brown

  Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma

  Endocr Relat Cancer 18 (2) 221-234, doi:10.1530/ERC-10-0235 first published on 24 January 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
  • Supplementary Data

  OPEN ACCESS ARTICLE
• Select this article
  • Wael K Al-Delaimy,
  • Shirley W Flatt,
  • Loki Natarajan,
  • Gail A Laughlin,
  • Cheryl L Rock,
  • Ellen B Gold,
  • Bette J Caan,
  • Barbara A Parker,
  • and John P Pierce

  IGF1 and risk of additional breast cancer in the WHEL study

  Endocr Relat Cancer 18 (2) 235-244, doi:10.1530/ERC-10-0121 first published on 24 January 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
• Select this article
  • Susan Ha,
  • Rachel Ruoff,
  • Nicole Kahoud,
  • Thomas F Franke,
  • and Susan K Logan

  Androgen receptor levels are upregulated by Akt in prostate cancer

  Endocr Relat Cancer 18 (2) 245-255, doi:10.1530/ERC-10-0204 first published on 11 February 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
  • Supplementary Data
• Select this article
  • D Koeberle,
  • T Ruhstaller,
  • L Jost,
  • O Pagani,
  • K Zaman,
  • R von Moos,
  • C Oehlschlegel,
  • S Crowe,
  • C Pilop,
  • and B Thuerlimann
  • , the Swiss Group for Clinical Cancer Research (SAKK)

  Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)

  Endocr Relat Cancer 18 (2) 257-264, doi:10.1530/ERC-10-0317 first published on 11 February 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
• Select this article
  • J Sainz,
  • A Rudolph,
  • R Hein,
  • M Hoffmeister,
  • S Buch,
  • W von Schönfels,
  • J Hampe,
  • C Schafmayer,
  • H Völzke,
  • B Frank,
  • H Brenner,
  • A Försti,
  • K Hemminki,
  • and J Chang-Claude

  Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk

  Endocr Relat Cancer 18 (2) 265-276, doi:10.1530/ERC-10-0264 first published on 11 February 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
  • Supplementary Data
• Select this article
  • Kathrin Zitzmann,
  • Enrico de Toni,
  • Janina von Rüden,
  • Stephan Brand,
  • Burkhard Göke,
  • Rüdiger P Laubender,
  • and Christoph J Auernhammer

  The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells

  Endocr Relat Cancer 18 (2) 277-285, doi:10.1530/ERC-10-0108 first published on 11 February 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
• Select this article
  • Alexandru Saveanu,
  • Mihaela Muresan,
  • Catherine De Micco,
  • David Taieb,
  • Anne-Laure Germanetti,
  • Frederic Sebag,
  • Jean-François Henry,
  • Laurent Brunaud,
  • Alain Enjalbert,
  • Georges Weryha,
  • and Anne Barlier

  Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas

  Endocr Relat Cancer 18 (2) 287-300, doi:10.1530/ERC-10-0175 first published on 18 February 2011
  • Abstract
  • Full Text
  • Full Text (PDF)
  • Figures Only
  • Supplementary Data